Advertisement
Singapore markets close in 1 hour 31 minutes
  • Straits Times Index

    3,343.37
    +11.67 (+0.35%)
     
  • Nikkei

    39,341.54
    -325.53 (-0.82%)
     
  • Hang Seng

    17,718.01
    -371.92 (-2.06%)
     
  • FTSE 100

    8,224.78
    -0.55 (-0.01%)
     
  • Bitcoin USD

    60,726.09
    -905.80 (-1.47%)
     
  • CMC Crypto 200

    1,262.12
    -4.02 (-0.32%)
     
  • S&P 500

    5,477.90
    +8.60 (+0.16%)
     
  • Dow

    39,127.80
    +15.64 (+0.04%)
     
  • Nasdaq

    17,805.16
    +87.50 (+0.49%)
     
  • Gold

    2,312.50
    -0.70 (-0.03%)
     
  • Crude Oil

    80.79
    -0.11 (-0.14%)
     
  • 10-Yr Bond

    4.3160
    +0.0780 (+1.84%)
     
  • FTSE Bursa Malaysia

    1,583.47
    -7.48 (-0.47%)
     
  • Jakarta Composite Index

    6,955.52
    +49.88 (+0.72%)
     
  • PSE Index

    6,390.58
    +77.47 (+1.23%)
     

Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval

Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval

Pfizer currently dominates the market for pneumococcal vaccines, which protect against bacterial infections that can cause pneumonia and meningitis, among other conditions. Merck, however, has been nipping at Pfizer’s heels for years. The company sells Vaxneuvance and Pneumovax 23, pneumococcal vaccines with combined 2023 revenue of $1.1 billion.